Philips’ MR-Only Simulation Nabs FDA Clearance

The FDA has granted Philips a 510(k) clearance for its MR-only MRCAT, designed for prostate cancer radiation treatment planning, the company announced Wednesday. 

Compared to the MR-CT approach, the MR-only solution removes the risk of image misalignment and registration uncertainties. The MR-only approach alleviates the need for additional patient scans.

The simulation is a part of the company’s Ingenia MR-RT platform, and let’s physicians rely on a single-modality imaging approach. — Anisa Jibrell